Figure 3.

Overview of the IA delivery paradigm of radioembolics and radiopeptides. The radioembolic (A) becomes lodged in the smaller arterial vessels and will not cross over into the venous system. Conversely, radiopeptides (B) will enter the tumor space and bind to specific cancer receptors. Not all radiopeptides will be retained in the tumor and will instead travel systemically through the venous system. This allows for a higher accumulation of the radiopeptide in the tumor while still giving a systemic dose for satellite tumor-site treatment. In the tumor diagram, green cells are tumor cells expressing the specific marker, while red and blue cells are non-targeted tumor microenvironment cells. Figure 3 tumor vasculature: © Kevin Brennan 2023.